Price
CHART BY
Frequently asked questions
What is United Therapeutics's market capitalization?
The market capitalization of United Therapeutics is $21.32B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is United Therapeutics's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for United Therapeutics is 17.78. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for United Therapeutics?
United Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $27.96. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for United Therapeutics's stock?
Currently, 16 analysts cover United Therapeutics's stock, with a consensus target price of $664.33. Analyst ratings provide insights into the stock's expected performance.
What is United Therapeutics's revenue over the trailing twelve months?
Over the trailing twelve months, United Therapeutics reported a revenue of $3.15B.
What is the EBITDA for United Therapeutics?
United Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.49B. EBITDA measures the company's overall financial performance.
What is the free cash flow of United Therapeutics?
United Therapeutics has a free cash flow of $1.09B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does United Therapeutics have, and what sector and industry does it belong to?
United Therapeutics employs approximately 1,400 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of United Therapeutics's shares?
The free float of United Therapeutics is 41.45M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $21.32B
- EPS (TTM)
- $27.96
- Free Float
- 41.45M
- P/E ratio (TTM)
- 17.78
- Revenue (TTM)
- $3.15B
- EBITDA (TTM)
- $1.49B
- Free Cashflow (TTM)
- $1.09B
Pricing
- 1D span
- $496.22$508.60
- 52W span
- $396.42$608.63
Analyst Ratings
The price target is $664.33 and the stock is covered by 16 analysts.
Buy
13
Hold
3
Sell
0
Information
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
- Employees
- 1,400
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- UTHR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet